MDBH — MDB Capital Holdings, LLC Class A common

MDB Capital Holdings Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• MDB Capital reported operating expenses of approximately $5.9 million for the first three quarters of 2025.
• The company expects a significant revenue boost in Q4, which will help offset operating expenses.
• The firm has notable equity positions in upcoming IPOs, specifically Paulex Bio and Buda Juice, which are anticipated to provide substantial upside for shareholders.

2. Strategic Updates and Business Highlights:

• CEO Chris Marlett emphasized MDB's unique position in the public venture space, highlighting a track record of successful IPOs and a goal to scale operations from launching one company every 18 months to 3-5 launches per year.
• The firm is actively curating a pipeline of opportunities, with 4-5 companies in late-stage negotiations for potential launches.
• MDB is focusing on transforming early-stage companies into public entities with strong market potential, leveraging community involvement for sourcing ideas and partnerships.
• Marlett expressed optimism about the microcap market's resurgence, citing increasing demand for transparency and liquidity in public markets.

3. Forward Guidance and Outlook:

• The company anticipates closing two IPOs (Paulex and Buda Juice) in the near term, marking a significant milestone as it would be the first time MDB has launched two companies in one quarter.
• MDB aims to continue building its community to support its operational needs and enhance its pipeline of public venture opportunities.
• Marlett is bullish on the microcap market's recovery, suggesting that the firm is well-positioned to capitalize on this trend.

4. Bad News, Challenges, or Points of Concern:

• The stock price has declined significantly, trading around $3.40 from an IPO price of $12, raising concerns among shareholders about the company's current valuation and market sentiment.
• The broader microcap market has faced challenges, leading to skepticism about MDB's ability to navigate through these tough conditions.
• There are ongoing concerns regarding dilution as MDB's portfolio companies may need to raise additional capital, impacting shareholder ownership percentages.
• Marlett acknowledged the need for improved investor relations to better communicate the company's value proposition and address market perceptions.

5. Notable Q&A Insights:

• In response to questions about dividends, Marlett indicated that distributions would be considered once there is a developed market for the stock and sufficient trading volume.
• He addressed concerns regarding eXoZymes, stating that the company is pivoting towards launching new ventures rather than focusing solely on fee-for-service models.
• Marlett discussed the anticipated FDA approval for HeartBeam, emphasizing its potential to revolutionize healthcare with a portable ECG device.
• The conversation highlighted the need for MDB to enhance its investor relations efforts to better articulate its value and growth potential amidst a challenging market environment.

Overall, MDB Capital Holdings is navigating a complex market landscape with a focus on scaling its operations and leveraging its unique public venture model while addressing shareholder concerns about stock performance and market conditions.